Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

By M. Murtaza, S. Dawson, D. Tsui, D. Gale, T. Forshew, A. Piskorz, C. Parkinson, S. Chin, Z. Kingsbury, A. Wong and 8 more. Nature, 2013

1,612 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1c390dba5d43a73c7cbe6eb24433b3d71c2a5ca7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Nicholas McGranahan
2. Charles Swanton
3. A. Bardelli
4. Matthew Meyerson
5. Gad Getz
6. J. Reis-Filho
7. L. Diaz
8. Lawrence Loeb

In Oncology

1. Nicholas McGranahan
2. P. Jänne
3. J. Reis-Filho
4. Charles Swanton
5. J. Seoane
6. Gad Getz
7. Niko Beerenwinkel

In Pulmonary and Respiratory Medicine

1. P. Jänne
2. Charles Swanton
3. Nicholas McGranahan

Citations in the corpus

• Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA (2014, positive): “This study is one of several that have investigated plasma genotyping as a way of noninvasively detecting the EGFR T790M resistance mutation in lung cancer patients treated with EGFR kinase inhibitors.(13, 22-24) Yet this is the first study to demonstrate, across multiple patients, that serial asses”
• Liquid Biopsies: Genotyping Circulating Tumor DNA (2014, background): “Moreover, investigating plasma from patients can account for molecular heterogeneity, because ctDNA fragments are collected from all tumors in a patient’s body through circulation (Fig 2).(44,65) Accordingly, examination of ctDNA for genetic alterations present in the tumor tissue is, in reality, a ”
• Cancer Evolution: Mathematical Models and Computational Inference (2014, background): “It has been shown that from tumor DNA found in the plasma of patients, tumor load, and genetic heterogeneity of the cancer can be inferred without the need for invasive biopsy or surgery (Forshew et al. 2012; Dawson et al. 2013; Murtaza et al. 2013).”
• Systems biology of cisplatin resistance: past, present and future (2014, neutral): “In addition, great enthusiasm has been generated by the possibility to sequence the whole genome of neoplastic lesions, as first achieved for acute myeloid leukemia and quickly thereafter for various other malignancies.210–214 Further increasing the Cell Death and Disease potential of this approach,”
• Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma (2015, background): “Given that LC was confirmed at the autopsy of BMBC2, our results indicated that the CSF Genev Amino acid BM (1) BM (2) BM (3) Liver (1) Liver (2) Liver (3) Liver (4) Liver (5) Liver (6) Gastric CSF ctDNA Plasma ctDNA TBX3 K137fs TP53 P177fs MAP2K4 E372X NCOR1 R507X ASXL2 A1269I FLT3 T820S MET N1081H”